Appili Therapeutics to Attend BARDA Innovation Symposium 2025

Executive Summary

• Appili Therapeutics announced it will attend the BARDA Innovation Symposium on November 20, 2025 in Washington, D.C.
• The company highlighted a recently awarded up‑to US $40 million NIAID contract for its VXV‑01 fungal vaccine program (including a $3.6 M base period and optional $36.3 M funding).
• Appili disclosed that it has submitted additional U.S. federal funding proposals representing US $94 million in potential awards, with expected decisions in Q1 2026, underscoring its non‑dilutive financing strategy.

Key Details

• Conference Attendance: BARDA Innovation Symposium – November 20, 2025, Washington, D.C.
• NIAID Contract (VXV‑01):
• Total potential value: up to US $40 million.
• Base period funding: US $3.6 million.
• Optional additional funding: up to US $36.3 million for IND submission and Phase 1 trials.
• Federal Funding Proposals: Submitted proposals totalling US $94 million in potential awards; anticipated award decisions in Q1 2026.
• Cumulative Government Support: Over US $66 million secured to date across contracts and grants.
• Strategic Rationale: Attendance aims to strengthen relationships with BARDA and other U.S. agencies, reinforcing Appili’s non‑dilutive funding model and pipeline advancement.

Notable Quotes

“Government partnerships are central to Appili’s mission and business model… The recent up to US $40 million contract from NIAID … reflects the growing recognition of our capabilities in infectious‑disease and biodefense innovation.” – Dr. Don Cilla, President & CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the release.